As you may know, our understanding of cancer continues to evolve at a rapid pace. The identification of biomarkers that can play a role in determining patient care is a significant scientific advancement, and one that requires continued education. Since it has been determined that many of the tumors in Lynch syndrome patients can be characterized by MicroSatellite Instability High and MisMatch Repair Deficiency and those characteristics can inform treatment options with new therapies, it is important to be educated  and to know your tumor markers.